Nuron Biotech Inc.
This article was originally published in Start Up
Executive Summary
Founded by veterans of Pfizer, Nuron Biotech Inc. is developing a recombinant human interferon beta-1 free of human serum albumin and the aggregates that set off an immune response. Thus the start-up's lead candidate should not lose effectiveness or have the tolerability issues that plague existing interferon beta drugs. The company will move its agent directly into Phase III clinical trials in Europe this year.
You may also be interested in...
Deals Of The Week: Mersana/Endo, Nuron/Akshaya, Array BioPharma/Foundation Medicine
The Domain Associates/Rusnano tie-up looks new on the surface, but is driven by a familiar imperative – the need to find new funding streams for biotechs still working to build up their exit value.
Start-Up Previews (02/2011)
A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Emerging MS Treatments: Reading the Gilenya Tea Leaves," includes profiles of Allozyne, GeNeuro, Nuron Biotech and Receptos. Plus these Start-Ups Across Health Care: Intralink-Spine, NinePoint Medical, PanOptica and Urovalve.
Receptos Inc.
Receptos isn't the only company in the G-coupled protein receptor oral MS drug arena, but it believes its proprietary S1P1 agonist will improve on Novartis' first-in-class S1P1 modulator Gilenya. Unlike Gilenya, which hits four of the five S1P receptor subtypes, the Receptos molecule binds selectively to S1P1 and has a predicted human half-life of approximately one day, potentially improving the safety profile and reducing complications for MS patients.